

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications

May 2019 CPT® Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications that have been submitted for consideration by the CPT Editorial Panel at its May 2019 meeting are listed below. These applications will be included in the proposed Panel agenda that will be posted to the AMA website on March 8, 2019. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full May Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 1002X4, 234X2X, 0301XT) below are placeholder codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31st of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31st of each year.**

Upon review of these applications, if the reviewer believes that they will need to provide comment on an issue, they should send a request for a copy of the application and associated materials to [Michael Pellegrino](#). This request for review of the agenda materials should contain the identity of the interested party seeking such and a brief summary of the basis for the request (e.g., associated vendor/ industry representative).

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form. Please follow the instructions in the correspondence that accompanies the materials.

Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders	
Request for Code Change Application Materials	March 8
Submission of Written Comments	March 15

During the time between now and the Panel meeting, this listing of Pathology/Laboratory code change applications may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the May 2019 meeting, which will be published on or before June 10, 2019 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

Tab #	Name	Code #	Request-Description
7	Non Face-to-Face Review and MDM of Lab Results	99XXX	Request to add XXXXX to report non face-to-face medical decision making for laboratory test results
16	Adalimumab Therapeutic Drug Assay	80XX0	Request to add 80XX0 to identify TDA for Adalimumab
17	Infliximab Therapeutic Drug Assay	80XX1	Request to add 80XX1 to identify TDA for Infliximab
18	Lacosamide Therapeutic Drug Assay	80XX2	Request to add 80XX2 to identify TDA for Lacosimide
19	Posaconazole Therapeutic Drug Assay	802X0	Request to add 802X0 to identify TDA for Posaconazole
20	Vedolizumab Therapeutic Drug Assay	802XX	Request to add 802XX to identify TDA for Vedolizumab

Tab #	Name	Code #	Request-Description
21	Voriconazole Therapeutic Drug Assay	802X1	Request to add 802X1 to identify TDA for Voriconazole
22	Tier 1-Genome-Wide CN-SNP Array in Neoplasia	81230 81406	Request to revise 81230, and 81406 to include oncology CN SNP array
23	Tier 1 UGT1A1	813XX	Request to add 813XX to report UDP glucuronosyltransferase 1 family, polypeptide A1, full gene analysis
24	Tier 2 to Tier 1 Cytogenomic Microarray for Neoplasia	81XX0 81406	Request to add 81XX0 as a Tier 1 to report cytogenomic microarray analysis
25	GSP Familial Hypercholesterolemia	814XX	Request to add 814XX to report genomic sequencing panel for familial hypercholesterolemia (FH)
26	GSP Lynch Syndrome Panel	814X0	Request to add 814X0 to report genomic sequencing panel for Lynch syndrome
27	GSP Targeted-Solid Organ or Hematolymphoid Neoplasm	814X1	Request to add 814X1 to report targeted genomic sequence analysis panel for solid organ or hematolymphoid neoplasm
28	MAAA-Breast Cancer Recurrence Risk	815X0	Request to add 815X0 to identify 12-gene RNA test for breast cancer tumor biology & cx trxmnt choice
29	MAAA Prostate Cancer Metastasis Risk Score	815XX	Request to add MAAA 815XX to report prostate cancer metastasis risk score
30	Mycoplasma Genitalium Infectious Agent Detection	8XXXX	Request to add 8XXXX to report genitalium infectious agent detection